Healthcare: Are These Two Biotech Stocks Too Risky To Buy?​

<p><span style="font-family: Calibri, Arial, Helvetica, sans-serif; font-size: 16px; line-height: 24px;">MannKind and Orexigen: two companies with big promise, but can they deliver on profit? Healthcare analyst Michael Douglass and healthcare contributor Todd Campbell discuss the risks facing these biotech stocks.</span></p>